Ying Cheng
A5057704753- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Thyroid Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Lymphocytic Leukemia Research
- BRCA gene mutations in cancer
- Colorectal and Anal Carcinomas
- Esophageal Cancer Research and Treatment
Jilin Province Tumor Hospital
2016-2025
Suzhou University of Science and Technology
2025
Wenzhou Medical University
2024-2025
University of Science and Technology of China
2024
Beihang University
2022-2024
Hunan Agricultural University
2022-2024
Qilu University of Technology
2024
Xinjiang Agricultural University
2024
Second Affiliated Hospital of Nanchang University
2023-2024
Nanchang University
2023-2024
Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients previously untreated, mutation–positive advanced non–small-cell lung cancer (NSCLC).
Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, plus was shown to significantly prolong overall survival among nonsquamous NSCLC.
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients mutation–positive advanced non–small-cell lung cancer (NSCLC). The showed longer progression-free survival than comparator (hazard ratio for disease progression or death, 0.46). Data from final...
Purpose There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in gastroesophageal junction adenocarcinoma whom at least prior chemotherapy had failed. Patients Methods This was randomized, double-blind, placebo-controlled phase III trial. from 32 centers...
IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement overall survival (OS) and progression-free (PFS) versus placebo CP/ET. Updated OS, disease progression patterns, safety, exploratory biomarkers (PD-L1,...
<h3>Importance</h3> Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated squamous cell carcinoma. <h3>Objective</h3> To evaluate efficacy and adverse events of camrelizumab plus chemotherapy vs placebo as a treatment <h3>Design, Setting, Participants</h3> This randomized, double-blind, placebo-controlled,...
Patients with metastatic gastric cancer (mGC) who do not respond to or experience progression second-line chemotherapy have no treatment options that clearly confer a survival benefit. This trial investigated the safety and efficacy of apatinib, an inhibitor vascular endothelial growth factor receptor, as option for heavily pretreated patients mGC.Patients experienced failure at least two chemotherapeutic regimens were randomly assigned receive placebo (group A), apatinib 850 mg once daily...
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and activating mutations EGFR, reported significant improvement progression-free survival dacomitinib. The mature overall (OS) analysis for the intention-to-treat population is presented here. Patients Methods In this multinational, multicenter study, age 18 years or older (≥ 20 Japan Korea) who had an Eastern Cooperative...
IntroductionData on immuno-oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab predominantly patient population with previously treated NSCLC.MethodsCheckMate 078 was randomized, open-label, phase III clinical trial from China, Russia, Singapore squamous or nonsquamous NSCLC that had progressed during/after platinum-based doublet chemotherapy (ClinicalTrials.gov: NCT02613507). Patients EGFR/ALK alterations were...
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We report 5-year efficacy and safety outcomes phase III KEYNOTE-407 study (ClinicalTrials.gov identifier:...
Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. The objective of this study was to assess the safety efficacy third-line anlotinib for patients with refractory advanced non-small-cell lung cancer (RA-NSCLC).Eligible were randomised 1 : receive (12 mg per day, os; days 1-14; 21 cycle) or placebo. primary end point progression-free survival (PFS).A total 117 eligible enrolled from 13 clinical centres in China...
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selective for EGFR-TKI-sensitizing and
To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation-positive non-small-cell lung cancer.This was a multicenter (17 centers China), open-label, phase II, randomized controlled trial erlotinib versus gemcitabine plus cisplatin (GC chemotherapy) therapy patients with stage IIIA-N2 cancer mutations exon 19 or 21 (EMERGING). Patients received 150 mg/d (neoadjuvant therapy, 42 days;...